As per our latest research analysis, the size of the Global Musculoskeletal Diseases Market is predicted to grow at an impressive CAGR in the next 5 years forecast timespan.
Musculoskeletal diseases are injuries/pain in the human musculoskeletal system, which also includes the joints, muscles, nerves, tendons, ligaments, and structures that support limbs, neck and back. These are caused by sudden exertion, or they can arise from making the same motions repeatedly. With increasing age the risk of musculoskeletal diseases increases. Also obese people have high risk of musculoskeletal diseases.
The global Musculoskeletal Diseases market is developing at an exceptionally quick pace. The significant drivers are increase in prevalence of musculoskeletal disorders. Factors like unmet medical needs in developing nations and growing need of drugs related to bones will boost this industry.
REPORT COVERAGE:
|
REPORT METRIC |
DETAILS |
|
Market Size Available |
2019 to 2025 |
|
Base Year |
2019 |
|
Forecast Period |
2020 to 2025 |
|
Segments Covered |
By Type, Type of Molecules, Treatment and Region |
|
Various Analyses Covered |
Global, Regional & Country Level Analysis, Segment-Level Analysis, DROC, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities |
|
Regions Covered |
North America, Europe, APAC, Latin America, Middle East & Africa |
|
Market Leaders Profiled |
AbGenomics International, AB Sciences, Ablynx, Akron Molecules, Johnson & Johnson, F. Hoffmann-La Roche, Pfizer,Eli Lilly, Adheron, Alder BioPharmaceuticals, Bioiberica, Bone Therapeutics, Edding Pharm, Boehringer Ingelheim, Can-Fite BioPharma, Celltrion, Celgene Corp., Cellular Biomedicine, ChemoCentryx, Cerapedics, Eupraxia Pharmaceuticals, and GlaxoSmithKline |
This research report on the Global Musculoskeletal Diseases Market segmented and sub-segmented into the following categories and analyzed market size and forecast for each segment until 2024.
Musculoskeletal Diseases Market Analysis – By Type:
On the basis of type, the Rheumatoid arthritis segment has high prevalence and therefore has the largest market share.
Musculoskeletal Diseases Market Analysis – By Type of Molecules:
On the basis of type of molecules, the Biologics segment is expected to have the largest market share. Biologics have complex structure which does not allow easy identification or characterization which is driving this segment.
Musculoskeletal Diseases Market Analysis – By Treatment:
Regional Analysis:
North America has the largest market share owing to factors like increased use of biologic drugs for treating various musculoskeletal diseases, increasing access to medical and healthcare facilities and introduction of novel biologics.
List of key competitors dominating the Global Musculoskeletal Diseases Market profiled in this report are:
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Type
5.1.1 Introduction
5.1.2 Rheumatoid Arthritis
5.1.3 Osteoarthritis
5.1.4 Osteoporosis
5.1.5 Psoriatic Arthritis
5.1.6 Ankylosing Spondylitis
5.1.7 Fibromyalgia
5.1.8 Others
5.1.9 Y-o-Y Growth Analysis, By Type
5.1.10 Market Attractiveness Analysis, By Type
5.1.11 Market Share Analysis, By Type
5.2 Type Of Molecules
5.2.1 Introduction
5.2.2 Biologics
5.2.3 Small Molecules
5.2.4 Y-o-Y Growth Analysis, By Type Of Molecules
5.2.5 Market Attractiveness Analysis, By Type Of Molecules
5.2.6 Market Share Analysis, By Type Of Molecules
5.3 Treatment
5.3.1 Introduction
5.3.2 Biologics
5.3.3 Corticosteroids
5.3.4 Parathyroid Hormone
5.3.5 Protein Therapy
5.3.6 Selective Estrogen Receptor Modulators
5.3.7 Synthetic Bone Graft
5.3.8 Composite Grafts
5.3.9 Demineralized Bone Matrix
5.3.10 BMPS
5.3.11 Y-o-Y Growth Analysis, By Treatment
5.3.12 Market Attractiveness Analysis, By Treatment
5.3.13 Market Share Analysis, By Treatment
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Type
6.1.3.3 By Type Of Molecules
6.1.3.4 By Treatment
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Type
6.1.4.3 By Type Of Molecules
6.1.4.4 By Treatment
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Type
6.1.5.3 By Type Of Molecules
6.1.5.4 By Treatment
6.2 North America
6.1.1 Introduction
6.1.2 United States
6.1.3 Canada
6.3 Europe
6.2.1 Introduction
6.2.2 U.K
6.2.3 Spain
6.2.4 Germany
6.2.5 Italy
6.2.6 France
6.4 Asia-Pacific
6.3.1 Introduction
6.3.2 China
6.3.3 India
6.3.4 Japan
6.3.5 Australia
6.3.6 South Korea
6.5 Latin America
6.4.1 Introduction
6.4.2 Brazil
6.4.3 Argentina
6.4.4 Mexico
6.4.5 Rest of Latin America
6.6 Middle East & Africa
6.5.1 Introduction
6.5.2 Middle-East
6.5.3 Africa
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Johnson & Johnson Private Limited
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Stryker Corporation
8.3 Akron Molecules
8.4 Adheron
8.5 Bone Therapeutics
8.6 Boehringer Ingelheim
8.7 ChemoCentryx
8.8 Daiichi Sankyo
8.9 GlaxoSmithKline
8.10 Eupraxia Pharmaceuticals
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
